Skip to main content
Premium Trial:

Request an Annual Quote

Windfall from CombiMatrix Settlement Turbo-charges Nanogen s Q4 Revenue

NEW YORK, Feb. 6 - Nanogen today reported a surge in fourth-quarter revenues atop a slight increase in R&D spending and strong net income. However, most of the revenue and earnings were the result of a windfall from a legal settlement in October.


For the period ended Dec. 31, Nanogen reported $12.1 million in revenue, up from $2.3 million one year ago. The company said, however, that receipts from sponsored research fell to $375,000 from $1.2 million year over year. Similarly, sales in the quarter fell to $511,000 from $691,000, Nanogen said.


There were two bright spots in the quarter: contracts and grants increased to $414,000 from $376,000 year over year, and CombiMatrix handed over $10.8 million as part of its defeat in a patent-infringement lawsuit.


Fourth-quarter R&D spending at Nanogen, meantime, increased to $5.3 million from $4.5 million one year ago. Consequently, the company posted a net income of $2 million, or $.09 per share, compared with a net loss of $7.5 million, or $.35 per share, in the fourth quarter 2001.


Nanogen said it had roughly $53 million in cash, cash equivalents, and short-term investments as of Dec. 31.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.